Fremanezumab for the Preventive Treatment of Chronic Migraine
DOI: https://doi.org/10.1056/NEJMoa1709038
2019-10-03
Abstract:Background Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene–related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine. Methods In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single dose of 675 mg at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), or matching placebo. Both fremanezumab and placebo were administered by means of subcutaneous injection. The primary end point was the mean change from baseline in the average number of headache days (defined as days in which headache pain lasted ≥4 consecutive hours and had a peak severity of at least a moderate level or days in which acute migraine–specific medication [triptans or ergots] was used to treat a headache of any severity or duration) per month during the 12 weeks after the first dose. Results Of 1130 patients enrolled, 376 were randomly assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo. The mean number of baseline headache days (as defined above) per month was 13.2, 12.8, and 13.3, respectively. The least-squares mean (±SE) reduction in the average number of headache days per month was 4.3±0.3 with fremanezumab quarterly, 4.6±0.3 with fremanezumab monthly, and 2.5±0.3 with placebo (P<0.001 for both comparisons with placebo). The percentage of patients with a reduction of at least 50% in the average number of headache days per month was 38% in the fremanezumab-quarterly group, 41% in the fremanezumab-monthly group, and 18% in the placebo group (P<0.001 for both comparisons with placebo). Abnormalities of hepatic function occurred in 5 patients in each fremanezumab group (1%) and 3 patients in the placebo group (<1%). Conclusions Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12-week trial. Injection-site reactions to the drug were common. The long-term durability and safety of fremanezumab require further study. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT02621931 .) Supported by Teva Pharmaceuticals. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Silberstein reports receiving consulting fees from Alder BioPharmaceuticals, Allergan, Amgen, Automatic Technologies, Avanir Pharmaceuticals, Curelator, Depomed, Dr. Reddy’s Laboratories, electroCore, Eli Lilly, eNeura, Insys Therapeutics, Supernus Pharmaceuticals, Teva Pharmaceuticals, Theranica Bio-Electronics, and Trigemina; Dr. Dodick, receiving consulting fees from Acorda Therapeutics, Alder BioPharmaceuticals, Allergan, Amgen, Automatic Technologies, Biocentric, Biohaven, Boston Scientific, Charleston Laboratories, CoLucid Pharmaceuticals, Dr. Reddy’s Laboratories, Eli Lilly, eNeura, Insys Therapeutics, Ladenburg Thalmann, Magellan, Merck, Neuro Assessment Systems, Pfizer, Promius Pharma, Teva Pharmaceuticals, Tonix Pharmaceuticals, Trigemina, Xenon Pharmaceuticals, and Zosano Pharma, owning stock options in Epien Medical, Mobile Health, and Nocira, and serving on the board of King-Devick Test; Dr. Bigal, being an employee of Teva Pharmaceuticals; Dr. Yeung, being an employee of Teva Pharmaceuticals; Dr. Goadsby, receiving consulting fees from Akita Biomedical, Alder BioPharmaceuticals, Avanir Pharmaceuticals, Cipla, Dr. Reddy’s Laboratories, electroCore, Novartis, Pfizer, Quest Diagnostics, Scion Pharmaceuticals, and Teva Pharmaceuticals, receiving consulting fees and grant support from Allergan, Amgen, Eli Lilly, and eNeura, receiving consulting fees from and holding stock options in Trigemina, and holding a patent, licensed to eNeura, for “Methods and systems for preventative migraine headache treatment” (WO2016090333 A1); Ms. Blankenbiller, being an employee of Teva Pharmaceuticals; Ms. Grozinski-Wolff, being an employee of Teva Pharmaceuticals; Dr. Yang, being an employee of Teva Pharmaceuticals; Ms. Ma, being an employ -Abstract Truncated-